Position statement for the diagnosis and management of anogenital warts

C. O'Mahony, M. Gomberg, M. Skerlev, A. Alraddadi, M. E. de las Heras-Alonso, S. Majewski, E. Nicolaidou, S. Serdaroğlu, Z. Kutlubay, M. Tawara, A. Stary, A. Al Hammadi, M. Cusini

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Anogenital warts (AGW) can cause economic burden on healthcare systems and are associated with emotional, psychological and physical issues. Objective: To provide guidance to physicians on the diagnosis and management of AGW. Methods: Fourteen global experts on AGW developed guidance on the diagnosis and management of AGW in an effort to unify international recommendations. Guidance was developed based on published international and national AGW guidelines and an evaluation of relevant literature published up to August 2016. Authors provided expert opinion based on their clinical experiences. Results: A checklist for a patient's initial consultation is provided to help physicians when diagnosing AGW to get the relevant information from the patient in order to manage and treat the AGW effectively. A number of frequently asked questions are also provided to aid physicians when communicating with patients about AGW. Treatment of AGW should be individualized and selected based on the number, size, morphology, location, and keratinization of warts, and whether they are new or recurrent. Different techniques can be used to treat AGW including ablation, immunotherapy and other topical therapies. Combinations of these techniques are thought to be more effective at reducing AGW recurrence than monotherapy. A simplified algorithm was created suggesting patients with 1–5 warts should be treated with ablation followed by immunotherapy. Patients with >5 warts should use immunotherapy for 2 months followed by ablation and a second 2-month course of immunotherapy. Guidance for daily practice situations and the subsequent action that can be taken, as well as an algorithm for treatment of large warts, were also created. Conclusion: The guidance provided will help physicians with the diagnosis and management of AGW in order to improve the health and quality of life of patients with AGW.

Original languageEnglish
Pages (from-to)1006-1019
JournalJournal of the European Academy of Dermatology and Venereology
Volume33
Issue number6
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Warts
Immunotherapy
Physicians
Expert Testimony

ASJC Scopus subject areas

  • Dermatology
  • Infectious Diseases

Cite this

O'Mahony, C., Gomberg, M., Skerlev, M., Alraddadi, A., de las Heras-Alonso, M. E., Majewski, S., ... Cusini, M. (2019). Position statement for the diagnosis and management of anogenital warts. Journal of the European Academy of Dermatology and Venereology, 33(6), 1006-1019. https://doi.org/10.1111/jdv.15570

Position statement for the diagnosis and management of anogenital warts. / O'Mahony, C.; Gomberg, M.; Skerlev, M.; Alraddadi, A.; de las Heras-Alonso, M. E.; Majewski, S.; Nicolaidou, E.; Serdaroğlu, S.; Kutlubay, Z.; Tawara, M.; Stary, A.; Al Hammadi, A.; Cusini, M.

In: Journal of the European Academy of Dermatology and Venereology, Vol. 33, No. 6, 01.01.2019, p. 1006-1019.

Research output: Contribution to journalArticle

O'Mahony, C, Gomberg, M, Skerlev, M, Alraddadi, A, de las Heras-Alonso, ME, Majewski, S, Nicolaidou, E, Serdaroğlu, S, Kutlubay, Z, Tawara, M, Stary, A, Al Hammadi, A & Cusini, M 2019, 'Position statement for the diagnosis and management of anogenital warts', Journal of the European Academy of Dermatology and Venereology, vol. 33, no. 6, pp. 1006-1019. https://doi.org/10.1111/jdv.15570
O'Mahony C, Gomberg M, Skerlev M, Alraddadi A, de las Heras-Alonso ME, Majewski S et al. Position statement for the diagnosis and management of anogenital warts. Journal of the European Academy of Dermatology and Venereology. 2019 Jan 1;33(6):1006-1019. https://doi.org/10.1111/jdv.15570
O'Mahony, C. ; Gomberg, M. ; Skerlev, M. ; Alraddadi, A. ; de las Heras-Alonso, M. E. ; Majewski, S. ; Nicolaidou, E. ; Serdaroğlu, S. ; Kutlubay, Z. ; Tawara, M. ; Stary, A. ; Al Hammadi, A. ; Cusini, M. / Position statement for the diagnosis and management of anogenital warts. In: Journal of the European Academy of Dermatology and Venereology. 2019 ; Vol. 33, No. 6. pp. 1006-1019.
@article{60fd1082a7ef433f8f5dad227704235f,
title = "Position statement for the diagnosis and management of anogenital warts",
abstract = "Background: Anogenital warts (AGW) can cause economic burden on healthcare systems and are associated with emotional, psychological and physical issues. Objective: To provide guidance to physicians on the diagnosis and management of AGW. Methods: Fourteen global experts on AGW developed guidance on the diagnosis and management of AGW in an effort to unify international recommendations. Guidance was developed based on published international and national AGW guidelines and an evaluation of relevant literature published up to August 2016. Authors provided expert opinion based on their clinical experiences. Results: A checklist for a patient's initial consultation is provided to help physicians when diagnosing AGW to get the relevant information from the patient in order to manage and treat the AGW effectively. A number of frequently asked questions are also provided to aid physicians when communicating with patients about AGW. Treatment of AGW should be individualized and selected based on the number, size, morphology, location, and keratinization of warts, and whether they are new or recurrent. Different techniques can be used to treat AGW including ablation, immunotherapy and other topical therapies. Combinations of these techniques are thought to be more effective at reducing AGW recurrence than monotherapy. A simplified algorithm was created suggesting patients with 1–5 warts should be treated with ablation followed by immunotherapy. Patients with >5 warts should use immunotherapy for 2 months followed by ablation and a second 2-month course of immunotherapy. Guidance for daily practice situations and the subsequent action that can be taken, as well as an algorithm for treatment of large warts, were also created. Conclusion: The guidance provided will help physicians with the diagnosis and management of AGW in order to improve the health and quality of life of patients with AGW.",
author = "C. O'Mahony and M. Gomberg and M. Skerlev and A. Alraddadi and {de las Heras-Alonso}, {M. E.} and S. Majewski and E. Nicolaidou and S. Serdaroğlu and Z. Kutlubay and M. Tawara and A. Stary and {Al Hammadi}, A. and M. Cusini",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/jdv.15570",
language = "English",
volume = "33",
pages = "1006--1019",
journal = "Journal of the European Academy of Dermatology and Venereology",
issn = "0926-9959",
publisher = "wiley",
number = "6",

}

TY - JOUR

T1 - Position statement for the diagnosis and management of anogenital warts

AU - O'Mahony, C.

AU - Gomberg, M.

AU - Skerlev, M.

AU - Alraddadi, A.

AU - de las Heras-Alonso, M. E.

AU - Majewski, S.

AU - Nicolaidou, E.

AU - Serdaroğlu, S.

AU - Kutlubay, Z.

AU - Tawara, M.

AU - Stary, A.

AU - Al Hammadi, A.

AU - Cusini, M.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Anogenital warts (AGW) can cause economic burden on healthcare systems and are associated with emotional, psychological and physical issues. Objective: To provide guidance to physicians on the diagnosis and management of AGW. Methods: Fourteen global experts on AGW developed guidance on the diagnosis and management of AGW in an effort to unify international recommendations. Guidance was developed based on published international and national AGW guidelines and an evaluation of relevant literature published up to August 2016. Authors provided expert opinion based on their clinical experiences. Results: A checklist for a patient's initial consultation is provided to help physicians when diagnosing AGW to get the relevant information from the patient in order to manage and treat the AGW effectively. A number of frequently asked questions are also provided to aid physicians when communicating with patients about AGW. Treatment of AGW should be individualized and selected based on the number, size, morphology, location, and keratinization of warts, and whether they are new or recurrent. Different techniques can be used to treat AGW including ablation, immunotherapy and other topical therapies. Combinations of these techniques are thought to be more effective at reducing AGW recurrence than monotherapy. A simplified algorithm was created suggesting patients with 1–5 warts should be treated with ablation followed by immunotherapy. Patients with >5 warts should use immunotherapy for 2 months followed by ablation and a second 2-month course of immunotherapy. Guidance for daily practice situations and the subsequent action that can be taken, as well as an algorithm for treatment of large warts, were also created. Conclusion: The guidance provided will help physicians with the diagnosis and management of AGW in order to improve the health and quality of life of patients with AGW.

AB - Background: Anogenital warts (AGW) can cause economic burden on healthcare systems and are associated with emotional, psychological and physical issues. Objective: To provide guidance to physicians on the diagnosis and management of AGW. Methods: Fourteen global experts on AGW developed guidance on the diagnosis and management of AGW in an effort to unify international recommendations. Guidance was developed based on published international and national AGW guidelines and an evaluation of relevant literature published up to August 2016. Authors provided expert opinion based on their clinical experiences. Results: A checklist for a patient's initial consultation is provided to help physicians when diagnosing AGW to get the relevant information from the patient in order to manage and treat the AGW effectively. A number of frequently asked questions are also provided to aid physicians when communicating with patients about AGW. Treatment of AGW should be individualized and selected based on the number, size, morphology, location, and keratinization of warts, and whether they are new or recurrent. Different techniques can be used to treat AGW including ablation, immunotherapy and other topical therapies. Combinations of these techniques are thought to be more effective at reducing AGW recurrence than monotherapy. A simplified algorithm was created suggesting patients with 1–5 warts should be treated with ablation followed by immunotherapy. Patients with >5 warts should use immunotherapy for 2 months followed by ablation and a second 2-month course of immunotherapy. Guidance for daily practice situations and the subsequent action that can be taken, as well as an algorithm for treatment of large warts, were also created. Conclusion: The guidance provided will help physicians with the diagnosis and management of AGW in order to improve the health and quality of life of patients with AGW.

UR - http://www.scopus.com/inward/record.url?scp=85064161234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064161234&partnerID=8YFLogxK

U2 - 10.1111/jdv.15570

DO - 10.1111/jdv.15570

M3 - Article

AN - SCOPUS:85064161234

VL - 33

SP - 1006

EP - 1019

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

SN - 0926-9959

IS - 6

ER -